Thursday, June 30, 2022

Hardly anyone, including doctors who perform this procedure

Hardly anyone, including doctors who perform this procedure





“Hardly anyone, including doctors who perform this procedure, realize that cryoablation can be used to generate a powerful immune response leading to one of the most successful cancer treatments that exist, particularly for patients with Stage III or IV cancer, where the options for treatment are most limited. Each year there are approximately 600,000 advanced cancers diagnosed in the U.S., which would otherwise be practically hopeless cases. But with this ablation technique, combined with immunotherapy, we now have the chance to save many of those lives. Moreover, patients with earlier stages of cancer who would otherwise suffer through toxic chemotherapy and radiation now have more effective choices of treatment with far fewer side effects. I like to call this combination therapy AblationVax™ because of how it optimizes the body’s immune system, similar to how vaccines do.
When I was in medical school and early residency and learned about the potential of this technique to treat cancer, I thought it was the most amazing thing I had heard and assumed word of this new strategy would spread quickly and all oncologists would jump on board. I recognized that the future of cancer treatment would be to target the tumor directly using minimally invasive techniques and image guidance, but I have since discovered that these ablation techniques have been slow to catch on. Even now, years later, the techniques are vastly under-utilized.
It is for these reasons, I believe, that this procedure may not take off until the oncologists themselves learn to do it.”
–
Jason R Williams, MD DABR
Chief of Interventional Oncology
–
In order to read more you can download a free copy of my book in the following link

The post Hardly anyone, including doctors who perform this procedure appeared first on Williams Cancer Institute.



source https://williamscancerinstitute.com/hardly-anyone-including-doctors-who-perform-this-procedure/?utm_source=rss&utm_medium=rss&utm_campaign=hardly-anyone-including-doctors-who-perform-this-procedure
Posted by at No comments:

Tuesday, June 28, 2022

Combination immunotherapy is generally more effective than any single agent.

Combination immunotherapy is generally more effective than any single agent.





“The anti-cancer immune response is as complex as is cancer itself. It is highly unlikely that one agent alone is sufficient to generate an effective anti-cancer immune response. Not only does CTLA-4 help tumors to suppress the immune response against them, PD-1 also plays an important role.
It has already been shown in clinical trials that the combination of anti-CTLA-4 and anti-PD-1 inhibitors is significantly more effective than either one alone. Just recently the FDA has added approvals of this combination for certain melanoma, kidney and colon cancers. Unfortunately, just as success increases, so does the cost and side effects of the two drugs just as significantly. This is one reason that we inject the medications into the tumor microenvironment, where they need to be. You want the immune response to be directed against the tumor, and where that is more likely to occur is at the tumor site. Once the immune system “learns” how to respond in one location, it is better able to attack cancer elsewhere in the body.
In addition, a treatment such as cryoablation, which is the direct freezing of the tumor, has its own immune-stimulating properties. It can be considered an additional form of immunotherapy to be used with immune checkpoint inhibitors. And because ablation is minimally invasive and tumors are treated with a needle under image guidance, it is the perfect opportunity to administer other immune agents, such as the checkpoint inhibitor drugs, directly into the tumor, at the same time, in one procedure.
Throughout the history of modern medicine, we have found many remarkable powerhouse treatment combinations. A great example is the treatment of HIV/AIDS. Just a few decades ago, an HIV diagnosis was a terminal one. But the current medications used today in combination have had great success and patients can live long, relatively normal lives with their disease. But when these same drugs are used alone, there is only a modest survival increase. Hence, the lessons we have learned in treating HIV patients supports the importance of combination therapy in treating disease, and cancer is no different.
Immune checkpoint inhibitors not only help unlock a natural immune response, they can be essential for helping other immune therapies turn from bust to boom. It’s that synergistic immune response that enables cancer treatments to become far more effective than ever before. While our knowledge of immunotherapy is still developing, we have finally reached a point where cancer patients—like former President Jimmy Carter—can recover from malignant and fast-growing tumors previously thought hopeless. And when I talk about hope, I’m not talking about just passively sitting back and hoping for a cure. I’m talking about taking charge of the recovery process by doing everything possible to give the immune system a fighting chance against cancer.”
Jason R Williams, MD DABR
Chief of Interventional Oncology
In order to read more you can download a free copy of my book in the following link

The post Combination immunotherapy is generally more effective than any single agent. appeared first on Williams Cancer Institute.



source https://williamscancerinstitute.com/combination-immunotherapy-is-generally-more-effective-than-any-single-agent/?utm_source=rss&utm_medium=rss&utm_campaign=combination-immunotherapy-is-generally-more-effective-than-any-single-agent
Posted by at No comments:

Friday, June 24, 2022

Typically your health insurance will not cover the costs of the drugs without FDA approval for your specific form of cancer, but combining immunotherapy with cryoablation or directly injecting the drugs into the tumor can drastically reduce the costs of medications.

HelloTypically your health insurance will not cover the costs of the drugs without FDA approval for your specific form of cancer, but combining immunotherapy with cryoablation or directly injecting the drugs into the tumor can drastically reduce the costs of medications.





“Unfortunately, insurance carriers will almost never provide coverage for a drug used to treat a condition that the FDA hasn’t approved it to treat. That means that if the drug your physician prescribes has not been approved by the FDA to treat the specific form of cancer you have, it may be almost impossible for him or her to offer you a standard immunotherapy treatment that is not directly covered by insurance, even if it may work. Yervoy, for example, may be covered by your insurance carrier for treating certain cases of melanoma, but not for treating other cancers. With a price tag at over $30,000 per infusion—and a course of treatment requiring a minimum of four infusions—it remains a treatment that many patients cannot afford. Bristol-Myers Squibb, the makers of Yervoy, does offer a patient-assistance program that may reduce cost, but it may still be such a steep price beyond the reach of many. There is also the difficulty of finding doctors who may be willing to offer these medications “off-label.” Also keep in mind that we are mainly discussing advanced, Stage IV patients, for which standard therapies may have failed or been of limited success.
Even though the drugs are available outside the United States, where in most cases they would be much less expensive than they are in the U.S., immunotherapy pricing remains fairly steep throughout the world.
But don’t let the price of these drugs discourage you. The key aspect to injecting the drugs directly into the tumor, rather than into the bloodstream, means that even without ablation, it may be possible to achieve the same or better results with a fraction of the dose—and at a fraction of the costs.34 In other words, whereas standard immunotherapy treatment involves infusing the drugs into the bloodstream, by combining immunotherapy with cryoablation or directly injecting these medications into the tumor, the effectiveness of the treatment may be enhanced while the price of that treatment is dramatically reduced.”
Jason R Williams, MD DABR
Chief of Interventional Oncology
In order to read more you can download a free copy of my book in the following link

The post Typically your health insurance will not cover the costs of the drugs without FDA approval for your specific form of cancer, but combining immunotherapy with cryoablation or directly injecting the drugs into the tumor can drastically reduce the costs of medications. appeared first on Williams Cancer Institute.



source https://williamscancerinstitute.com/typically-your-health-insurance-will-not-cover-the-costs-of-the-drugs-without-fda-approval-for-your-specific-form-of-cancer-but-combining-immunotherapy-with-cryoablation-or-directly-injecting-the-dru/?utm_source=rss&utm_medium=rss&utm_campaign=typically-your-health-insurance-will-not-cover-the-costs-of-the-drugs-without-fda-approval-for-your-specific-form-of-cancer-but-combining-immunotherapy-with-cryoablation-or-directly-injecting-the-dru
Posted by at No comments:

Wednesday, June 22, 2022

What You Need to Know to Get Started: The Basics of Cancer Immunotherapy

What You Need to Know to Get Started: The Basics of Cancer Immunotherapy





“In essence, as powerful as the immune system is, cancer  has been even more intelligent. It is not just the fact that the  immune system fails to recognize cancer that has made cancer  so challenging to treat effectively, but also the fact that cancer  is actively able to avoid the immune system.
In simple terms, you can think of the immune system  as having two main divisions, one designed to attack  harmful foreign substances and the other to protect against  an overzealous immune response, acting as defense against  “autoimmunity”—the process of immune cells misperceiving  cells in the body as foreign invaders and attacking them by  mistake. I stress this again because it is important: The division
designed to protect the body from a mistaken immune attack  is known as the regulatory immune system. The regulatory  immune system is obviously critical to reduce the risk of  autoimmune diseases which arise when the immune system  thinks the body’s own cells are foreign ones and must be  destroyed. The regulatory immune system helps prevent these  mistaken attacks on the body’s own cells. You can think of  the protective, regulatory side of the immune system as being  the “brakes” and the attacking side as being the “gas pedal.”  No matter how much you push the gas, if the brakes are fully  applied you will go nowhere. Unfortunately, what that means  when it comes to cancer is that the regulatory portion of the  immune system prevents the rest of the immune system from  attacking cancer cells because those cells are masquerading  as normal, natural cells that belong there. Thus, failing to  recognize the cancer cells for what they are, the regulatory  immune system is an important protector of cancer.
Despite these challenges, the concept of teaching the  immune system to recognize cancer and destroy it has seemed  like the best chance to create a cure in a high percentage of  cancer patients. The immune system has its own intelligence  and it has memory, both of which are crucial to seek out  and kill cancer. A good immune response recognizes many  targets on a cancer, so-called cancer antigens, making it  harder for the cancer to hide. This is the weakness with some  of the one-dimensional treatments, which includes some  vaccines and original versions of CAR-T, which generally  target one antigen. Later in this book, I will discuss in more  detail how intra-tumoral immunotherapy, the injection of  immunotherapy directly into a cancer, may be a good solution  to this problem.”

In order to read more you can download a free copy of my book in the following link
 
Jason R Williams, MD, DABR

The post What You Need to Know to Get Started: The Basics of Cancer Immunotherapy appeared first on Williams Cancer Institute.



source https://williamscancerinstitute.com/what-you-need-to-know-to-get-started-the-basics-of-cancer-immunotherapy/?utm_source=rss&utm_medium=rss&utm_campaign=what-you-need-to-know-to-get-started-the-basics-of-cancer-immunotherapy
Posted by at No comments:

Friday, June 17, 2022

The Immunotherapy Revolution

The Immunotherapy Revolution




The post The Immunotherapy Revolution appeared first on Williams Cancer Institute.



source https://williamscancerinstitute.com/the-immunotherapy-revolution/?utm_source=rss&utm_medium=rss&utm_campaign=the-immunotherapy-revolution
Posted by at No comments:

INTRATUMORAL IMMUNOTHERAPY AND CRYOABLATION FOR CANCER – WELCOME TO Cabo San Lucas, Mexico.

INTRATUMORAL IMMUNOTHERAPY AND CRYOABLATION FOR CANCER – WELCOME TO Cabo San Lucas, Mexico.




The post INTRATUMORAL IMMUNOTHERAPY AND CRYOABLATION FOR CANCER – WELCOME TO Cabo San Lucas, Mexico. appeared first on Williams Cancer Institute.



source https://williamscancerinstitute.com/intratumoral-immunotherapy-and-cryoablation-for-cancer-welcome-to-cabo-san-lucas-mexico/?utm_source=rss&utm_medium=rss&utm_campaign=intratumoral-immunotherapy-and-cryoablation-for-cancer-welcome-to-cabo-san-lucas-mexico
Posted by at No comments:

Wednesday, June 15, 2022

DOES ACETAMINOPHEN DECREASE THE IMMUNE RESPONSE?

DOES ACETAMINOPHEN DECREASE THE IMMUNE RESPONSE?





Acetaminophen is one of the foremost frontline medications in relieving pain and discomfort. It’s relatively safe. It’s the most common and cheapest on the market. Of course, anything in excess can be harmful. A few pills too many or combined with alcohol, and it can cause severe liver failure or death. But is that the only risk it poses? It seems not for Immunotherapy patients.

An increased mortality rate of Immunotherapy patients taking Acetaminophen has led to several researchers conducting studies.
These studies have shown that the hazard (H) to progression-free survival rate (PFS) increases when introducing Acetaminophen. Influenced by Acetaminophen, the immune system upregulates Interleukin-10, an immune-suppressive cytokine that decreases inflammation. It also reduces cell death protein 1 (PD-1), which is involved in the immune system’s T-cell response. This makes it harder for the immune system to detect tumor cells.


The post DOES ACETAMINOPHEN DECREASE THE IMMUNE RESPONSE? appeared first on Williams Cancer Institute.



source https://williamscancerinstitute.com/does-acetaminophen-decrease-the-immune-response/?utm_source=rss&utm_medium=rss&utm_campaign=does-acetaminophen-decrease-the-immune-response
Posted by at No comments:

Monday, June 13, 2022

Breast Cancer Awareness: Questions & Answers

Breast Cancer Awareness: Questions & Answers




The post Breast Cancer Awareness: Questions & Answers appeared first on Williams Cancer Institute.



source https://williamscancerinstitute.com/breast-cancer-awareness-questions-answers/?utm_source=rss&utm_medium=rss&utm_campaign=breast-cancer-awareness-questions-answers
Posted by at No comments:

Friday, June 10, 2022

Did you know that you can reduce the risk of pancreatic cancer and improve immunotherapy response by doing aerobic exercise?

Did you know that you can reduce the risk of pancreatic cancer and improve immunotherapy response by doing aerobic exercise?





Thirty minutes of exercise a day can reduce the risk of pancreatic cancer by as much as 50%. Aerobic exercise produces adrenaline (the fight-or-flight hormone). Adrenaline can boost the immune response by enhancing how the body handles signal proteins like Interleukin-15, which activates and increases the proliferation and survival of T-cells, B-cells, and NK (natural killer) cells. For this reason, adrenaline acts as one of the keys to unlocking a broader immune response to pancreatic cancer. Aerobic exercise also releases endorphins that reduce anxiety and depression.

It should be noted that generally, after a surgical procedure, it is recommended to start physical activity gradually under the advice of your health provider.


The post Did you know that you can reduce the risk of pancreatic cancer and improve immunotherapy response by doing aerobic exercise? appeared first on Williams Cancer Institute.



source https://williamscancerinstitute.com/did-you-know-that-you-can-reduce-the-risk-of-pancreatic-cancer-and-improve-immunotherapy-response-by-doing-aerobic-exercise/?utm_source=rss&utm_medium=rss&utm_campaign=did-you-know-that-you-can-reduce-the-risk-of-pancreatic-cancer-and-improve-immunotherapy-response-by-doing-aerobic-exercise
Posted by at No comments:

DOSTARLIMAB AND THE AMAZING IMMUNOTHERAPY RESULTS IN RECTAL CANCER

DOSTARLIMAB AND THE AMAZING IMMUNOTHERAPY RESULTS IN RECTAL CANCER






The post DOSTARLIMAB AND THE AMAZING IMMUNOTHERAPY RESULTS IN RECTAL CANCER appeared first on Williams Cancer Institute.



source https://williamscancerinstitute.com/dostarlimab-and-the-amazing-immunotherapy-results-in-rectal-cancer/?utm_source=rss&utm_medium=rss&utm_campaign=dostarlimab-and-the-amazing-immunotherapy-results-in-rectal-cancer
Posted by at No comments:

Wednesday, June 8, 2022

Complete response in 12 Out of 12 Patients with Rectal Carcinoma using Immunotherapy

Complete response in 12 Out of 12 Patients with Rectal Carcinoma using Immunotherapy



On June 5, published by Cercek et al. in The New England Journal of Medicine, a small trial of 12 patients with stage 2-3 rectal cancer was treated with the PD-1 inhibitor, dostarlimab.   Amazingly, they reported that 12 out of 12 had a complete response. Clearly very exciting and goes with my feeling that most cancer patients need to be allowed to be treated with Immunotherapy, especially if other treatments have failed. There is one special consideration in the study; the patients had what is known as a mismatch repair deficient tumor. What is mismatch repair? It is the ability to fix incorrectly inserted bases of DNA that occur during the copying of the DNA. If this process does not function correctly, more DNA errors will accumulate. The more errors, the more different the cancer DNA will be from normal cells. This gives the immune system more targets, making cancer more receptive to Immunotherapy. Unfortunately, like many other cancers, mismatch deficiency is in the minority of colorectal cancer, 15% or less. Certainly, it is essential to identify patients with mismatch deficiency and consider Immunotherapy. That is undoubtedly a common practice in evaluating the biopsy of a tumor. There are also other aspects beyond mismatch repair, such as tumor mutational burden and other mutations associated with DNA repair. Also, in some cases, certain medications can be used to block DNA repair, potentially increasing the potential to respond to Immunotherapy.

There are a few questions that arise from this trial. One question is whether dostarlimab is superior to Opdivo or Keytruda, even though all are in the same class of drugs as PD-1 inhibitors. The results seemed similar in prior trials where dostarlimab and Keytruda were used. We may see more head-to-head trials to answer this question in the future. The next question is what can be done to make the majority of patients who don’t have mismatch deficiency respond as well. Though there are many complex aspects of the immune response, one key one is to increase the immune cell infiltration into cancer. One technique is injecting immune agents into the tumor that calls the immune cells to the tumor. This now alerts the immune cells to cancer and can increase the ability to respond to other Immunotherapy. This is a way to equalize the playing field for patients who don’t have mismatch repair to be more like those who do.

Certainly, this study further demonstrates to the public what we in the scientific community already knew, that it is possible to have incredible responses with Immunotherapy. And we know the playbook and can expand this out to the majority of other cancers. That is precisely what we are doing with our patients, bringing the treatments of the future to them today.

By Dr. Jason Williams


The post Complete response in 12 Out of 12 Patients with Rectal Carcinoma using Immunotherapy appeared first on Williams Cancer Institute.



source https://williamscancerinstitute.com/complete-response-in-12-out-of-12-patients-with-rectal-carcinoma-using-immunotherapy/?utm_source=rss&utm_medium=rss&utm_campaign=complete-response-in-12-out-of-12-patients-with-rectal-carcinoma-using-immunotherapy
Posted by at No comments:

Tuesday, June 7, 2022

IMMUNOTHERAPY AWARENESS MONTH | WILLIAMS CANCER INSTITUTE

IMMUNOTHERAPY AWARENESS MONTH | WILLIAMS CANCER INSTITUTE



The post IMMUNOTHERAPY AWARENESS MONTH | WILLIAMS CANCER INSTITUTE appeared first on Williams Cancer Institute.



source https://williamscancerinstitute.com/immunotherapy-treatment-against-breast-cancer-2/?utm_source=rss&utm_medium=rss&utm_campaign=immunotherapy-treatment-against-breast-cancer-2
Posted by at No comments:

Thursday, June 2, 2022

CANCER PREVENTION AND EARLY DETECTION.


Of all the causes of death, cancer remains the second-leading in the entire world. Maintaining a healthy diet and active lifestyle is vital in fighting this disease. Regular screenings such as mammograms, pap smears, colonoscopies, and prostate exams are essential for early detection, and early detection can be critical to treatment success.



The post CANCER PREVENTION AND EARLY DETECTION. appeared first on Williams Cancer Institute.



source https://williamscancerinstitute.com/cancer-prevention-and-early-detection/?utm_source=rss&utm_medium=rss&utm_campaign=cancer-prevention-and-early-detection
Posted by at No comments:

Wednesday, June 1, 2022

Immunotherapy vs Chemotherapy

IMMUNOTHERAPY VS CHEMOTHERAPY





When it comes to breaking down the differences between two cancer treatments and choosing
which is best, the ultimate goal is to take into consideration the individual factors and
circumstances each patient has. Each treatment will have its unique side effects and
considerations. We’ve simplified a couple of differences amongst both chemotherapy and
immunotherapy to help you better compare both treatments.
Chemotherapy
● Depletes the body’s immune system
● Decreases white blood cells count
● Causes drastic hair loss
● Causes nausea and vomiting
● Causes chemo brain (disruption in focus and concentration)
● Can be combined with immunotherapy
● Low metronomic dosing is an option
● Reduces tumor burden, making it easier for the immune system to fight
Immunotherapy
● May increase certain autoimmune diseases
● Can cause autoimmune pneumonitis
● Hormone imbalance may occur
● Cytokine Release Syndrome (CRS)
● Less invasive than chemotherapy
● When used in combination with other cancer treatments has been shown to improve the
overall treatment process
● Fewer side effects compared to chemotherapy

Follow us


The post Immunotherapy vs Chemotherapy appeared first on Williams Cancer Institute.



source https://williamscancerinstitute.com/blog-immunotherapy-vs-chemotherapy/?utm_source=rss&utm_medium=rss&utm_campaign=blog-immunotherapy-vs-chemotherapy
Posted by at No comments:
Subscribe to: Posts (Atom)